Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced its transition into a clinical-stage company with the initiation of its first clinical study for PH-762 targeting advanced melanoma. The company reported a net loss of $13.3 million for the year ended December 31, 2021, up from $8.8 million in 2020. The company holds $24.1 million in cash, sufficient to fund operations into the second quarter of 2023. Upcoming milestones include starting patient enrollment for PH-762 and new data presentations related to its pipeline in 2022.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the upcoming presentation of new preclinical data on its RNAi compound PH-894, targeting BRD4, at the AACR Annual Meeting 2022 in New Orleans from April 8-13, 2022. The poster session will discuss PH-894's potential to provide abscopal efficacy toward untreated distal tumors and enhance systemic anti-PD-1 antibody therapy effectiveness. The presentation, led by Benjamin Cuiffo and accessible in person and virtually, is scheduled for April 13, 2022, from 9:00 AM to 12:30 PM.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced the initiation of efficacy animal studies focusing on its INTASYL-based antiviral compounds against SARS-CoV-2. This follows earlier positive laboratory results. The compounds target two virus-related and one host-related target, with three compounds selected for further testing in a validated mouse model. The INTASYL platform's efficiency highlights its potential for rapid development of antiviral therapies to combat COVID-19 variants. The company's ongoing commitment includes immuno-oncology programs while addressing the pandemic's challenges.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) received regulatory clearance from the French National Agency for the Safety of Medicines and Health Products to initiate a clinical trial for its lead product candidate, PH-762, targeting melanoma. This Phase 1b trial will assess the safety, tolerability, and anti-tumor activity of PH-762, which works by reducing PD-1 expression to enhance cancer cell recognition and destruction by immune cells. The company aims to start dosing patients in Q1 2022, marking a significant milestone in the development of its INTASYL immuno-oncology platform.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, scheduled from January 10–13, 2022. Dr. Gerrit Dispersyn, the CEO, will present on the firm's innovative immuno-oncology therapeutics using its proprietary INTASYL™ RNAi platform, aimed at enhancing immune response against tumors. The presentation will be available on-demand starting at 7 a.m. EST on January 10. Interested parties can access the webcast through the company's website, where it will remain archived for 90 days.
Phio Pharmaceuticals (NASDAQ: PHIO) presented promising new data on its lead product candidate, PH-762, at the SITC 36th Annual Meeting. The study indicates that local administration of PH-762 in a hepatocarcinoma model not only inhibits the growth of treated tumors but also clears untreated distal tumors, suggesting a systemic immune response. Results showed that 80% of untreated tumors were completely cured, highlighting PH-762's potential as a new immunotherapy option with reduced systemic toxicity compared to traditional therapies. This data supports plans for a Phase 1 clinical trial in melanoma patients.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced its Q3 2021 financial results, reporting a net loss of $3.7 million or $0.28 per share, an increase from $2.3 million or $0.40 per share for Q3 2020. Cash and cash equivalents stood at $26.5 million as of September 30, 2021, expected to last until Q2 2023. The company aims to commence its first-in-human trial for PH-762 in Q1 2022 and expects to file a clinical trial application for PH-894 in H2 2022, showcasing the potential of its INTASYL technology in immuno-oncology.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that new data indicates a systemic immune response can be triggered by its lead product candidate, PH-762, after local administration. These findings will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington, D.C. from November 10-14, 2021. The relevant poster presentation is scheduled for November 12, 2021, at 7:00 am ET, showcasing potential advancements in immuno-oncology therapy.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced significant findings at the AACR-NCI-EORTC conference on October 7, 2021, regarding PH-894, its self-delivering RNAi compound targeting BRD4. The results indicate that PH-894 effectively silenced BRD4, enhancing T cell activation and tumor growth inhibition in vivo. This suggests PH-894 may serve as a promising immunotherapy option by reprogramming T cells. Phio is currently working on IND-enabling studies to advance PH-894 into clinical trials.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company specializing in immuno-oncology, announced two significant poster presentations at upcoming scientific conferences in October 2021. The first will occur at the AACR-NCI-EORTC Virtual International Conference from October 7-10, showcasing research on targeting BRD4 in T cells with self-delivering RNAi PH-894. The second presentation at the 8th Immunotherapy of Cancer Conference (ITOC8) on October 8-9 will focus on optimizing T lymphocytes for solid tumor therapy. For more details, visit their website.